Fundraising FoxNuvectis
Fort Lee, US · Founded 2020 · 1 known investors
Find your way into Nuvectis
Sign up to see every warm intro you have to Nuvectis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nuvectis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.
Founders & leadership
Investors · 1
How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$15.9M disclosed across 1 of 3 rounds · 2022–2026
▶$15.9MraisedAug 2022 · 19 investors · BiotechnologyRule 506(b)
- James OlivieroDirector
- Enrique PoradosuExecutive Officer
- Matthew KaplanDirector
- Michael CarsonExecutive Officer
- Kenneth HobermanDirector
- Ron BentsurExecutive Officer, Director
- Shay ShemeshExecutive Officer
- Offering amount
- $15.9M
- Amount sold
- $15.9M
- Sales commissions
- $1.4M
- Placement agents
- H.C. Wainwright & Co.
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nuvectis do?
- Nuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.
- Who are Nuvectis's investors?
- Nuvectis's investors include Pontifax Venture Capital.
- How much funding has Nuvectis raised?
- Nuvectis has disclosed $15.9M raised across 1 of its 3 known rounds.
- Where is Nuvectis headquartered?
- Nuvectis is headquartered in Fort Lee, US.